Guizhou Sanli Pharmaceutical Co Ltd (603439) - Total Liabilities
Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has total liabilities worth CN¥1.30 Billion CNY (≈ $190.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Guizhou Sanli Pharmaceutical Co Ltd (603439) equity growth momentum to track the company's year-over-year net asset growth rate.
Guizhou Sanli Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 603439 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Guizhou Sanli Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Wencan Die Casting Co Ltd
SHG:603348
|
China | CN¥5.11 Billion |
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
China | CN¥6.01 Billion |
|
Synergie SE
PA:SDG
|
France | €817.63 Million |
|
Calian Technologies Ltd
TO:CGY
|
Canada | CA$428.52 Million |
|
Zhongyin Babi Food Co. Ltd.
SHG:605338
|
China | CN¥482.41 Million |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
China | CN¥399.05 Million |
|
Gladstone Investment Corporation
NASDAQ:GAIN
|
USA | $641.21 Million |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
China | CN¥2.03 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Guizhou Sanli Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 603439 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Sanli Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.60 Billion ≈ $233.76 Million |
+31.90% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.22 Million |
+109.39% |
| 2022-12-31 | CN¥578.40 Million ≈ $84.64 Million |
+55.10% |
| 2021-12-31 | CN¥372.93 Million ≈ $54.57 Million |
+34.67% |
| 2020-12-31 | CN¥276.91 Million ≈ $40.52 Million |
+247.35% |
| 2019-12-31 | CN¥79.72 Million ≈ $11.67 Million |
+35.84% |
| 2018-12-31 | CN¥58.69 Million ≈ $8.59 Million |
-36.26% |
| 2017-12-31 | CN¥92.07 Million ≈ $13.47 Million |
+5.30% |
| 2016-12-31 | CN¥87.44 Million ≈ $12.79 Million |
+1.50% |
| 2015-12-31 | CN¥86.14 Million ≈ $12.60 Million |
-38.33% |
| 2014-12-31 | CN¥139.67 Million ≈ $20.44 Million |
+7.01% |
| 2013-12-31 | CN¥130.52 Million ≈ $19.10 Million |
-- |
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more